(Health-NewsWire.Net, April 28, 2017 ) Publisher's clinical trial report, "Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical Trials Review, H1, 2017" provides an overview of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) clinical trials scenario. This report provides top line data relating to the clinical trials on Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Publisher Clinical Trial Reports are generated using Publisher's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
For more information about this report: http://www.reportsweb.com/acute-lymphocytic-leukemia-all-acute-lymphoblastic-leukemia-global-clinical-trials-review-h1-2017 .
Report Scope
- The report provides a snapshot of the global clinical trials landscape - Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status - The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company - The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment - The Report provides enrollment trends for the past five years - Report provides latest news for the past three months
Request Sample Copy at http://www.reportsweb.com/inquiry&RW0001740905/sample .
Table of Contents
List of Tables 4 List of Figures 5 Report Guidance 6 Clinical Trials by Region 7 Clinical Trials and Average Enrollment by Country 8 Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11 Top Five Countries Contributing to Clinical Trials in Europe 12 Top Countries Contributing to Clinical Trials in North America 13 Top Five Countries Contributing to Clinical Trials in Middle East and Africa 14 Top Five Countries Contributing to Clinical Trials in Central and South America 15 Clinical Trials by G7 Countries: Proportion of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) to Oncology Clinical Trials 16 Clinical Trials by Phase in G7 Countries 18 Clinical Trials in G7 Countries by Trial Status 19 Clinical Trials by E7 Countries: Proportion of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) to Oncology Clinical Trials 21 Clinical Trials by Phase in E7 Countries 22 Clinical Trials in E7 Countries by Trial Status 23 Clinical Trials by Phase 24 In Progress Trials by Phase 25 Clinical Trials by Trial Status 26 Clinical Trials by End Point Status 27 Subjects Recruited Over a Period of Time 28 Clinical Trials by Sponsor Type 29 Prominent Sponsors 30 Top Companies Participating in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials 32 Prominent Drugs 34 Latest Clinical Trials News on Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) 35 Feb 23, 2017: Children's National Health System Experts Present Data on Novel Approach to Cell Therapy for Cancer Patients 35 Jan 31, 2017: ZIOPHARM Utilizing Non-Viral Sleeping Beauty Platform to Rapidly Produce CAR-Expressing T cells Advancing "Point-of-Care" Approach 35 Jan 09, 2017: Phase I Trial (CALL-1) for C-CAR011 in Adult Patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia (ALL) in China 36 Dec 22, 2016: Immunomedics Awarded Additional Intellectual Property Protection for IMMU-140, an Antibody-Drug Conjugate With Dual-Therapeutic Potential 36 Dec 19, 2016: Kancera reports positive results for fractalkine blocker KAN0440567 in preclinical models of pain caused by anti-cancer drugs 37 Dec 06, 2016: Juno Therapeutics Presents data on investigational CAR T cell product candidate JCAR017 at 58th American Society of Hematology 37 Dec 06, 2016: Juno Therapeutics Presents data on investigational CAR T cell product candidate JCAR-018 at 58th American Society of Hematology 38 Dec 06, 2016: Affimed Presents New Preclinical Data on AFM-11 at ASH 39 Dec 06, 2016: ARIAD Announces Data Presentations at American Society of Hematology Meeting 39 Dec 04, 2016: Novartis presents results from first global registration trial of CTL019 in pediatric and young adult patients with r/r B-ALL 40 Dec 04, 2016: Kite Pharma Reports 82 Percent of Patients Achieved Complete Remission in Preliminary Analysis from Phase 1 ZUMA-3 and ZUMA-4 Trials of KTE-C19 in Adult and Pediatric Patients with High Burden Relapsed/Refractory Acute Lymphoblastic Leukemia 41 Dec 03, 2016: In Clinical Trials, CAR T Cell Immunotherapy Continues to Yield Complete Responses in Children & Young Adults with Relapsed and Refractory Leukemia 41 Nov 30, 2016: Amgen Announces Presentation Of New Data In Acute Lymphoblastic Leukemia At ASH 2016 42 Nov 29, 2016: Sareum to Present TYK2 Cancer Research Programme at the 2016 AACR-NCI-EORTC International Conference 42 Clinical Trial Profile Snapshots 44 Appendix 1002 Abbreviations 1002 Definitions 1002 Research Methodology 1004 Secondary Research 1005 About Publisher 1006 Contact Us 1006 Disclaimer 1006 Source 1007
Inquire for Report at http://www.reportsweb.com/inquiry&RW0001740905/buying .
Contact Us: Call: +1-646-491-9876 Email: sales@reportsweb.com
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com
|